E2A t(1-19)(q23-p13) Qualitative Test: Booking, Price, and Results
About E2A t(1-19)(q23-p13) Qualitative Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | TCF3-PBX1 Qualitative Test, E2A-PBX1 Translocation Test, t(1;19) Translocation Detection, E2A/PBX1 Fusion Gene Test |
| Sample Type | Bone marrow aspirate and peripheral blood |
| Fasting Required | No fasting required |
| Report Time | 3 days |
| Recommended For | Children and adults suspected of or diagnosed with B-cell acute lymphoblastic leukaemia (B-ALL) |
| Price | Starting at ₹4,800 |
What is a E2A t(1-19)(q23-p13) Qualitative Test?
The E2A t(1-19)(q23-p13) Qualitative Test detects an abnormal fusion gene formed when two chromosomes swap segments, a change linked to a specific type of blood cancer. It is used to diagnose and monitor B-cell acute lymphoblastic leukaemia (B-ALL), a cancer that affects white blood cells. The test is also known as the TCF3-PBX1 Qualitative or E2A-PBX1 Translocation Test. Samples are collected from bone marrow and peripheral blood.
What Does a E2A t(1-19)(q23-p13) Qualitative Test Measure?
This test analyses genetic material from the sample to identify a specific chromosomal change. The method used is FISH (Fluorescence In Situ Hybridisation), which highlights abnormal gene arrangements under a microscope.
The test examines the following:
| Component | What It Looks For |
|---|---|
| TCF3-PBX1 fusion gene | Detects whether the TCF3 gene (chromosome 19) and PBX1 gene (chromosome 1) have abnormally fused together |
| t(1;19)(q23;p13) translocation | Identifies whether segments of chromosomes 1 and 19 have swapped positions |
| Qualitative result | Reports the fusion gene as either present (positive) or absent (negative) |
Why Is a E2A t(1-19)(q23-p13) Qualitative Test Done?
Doctors order this test when a patient shows signs that may point to a blood cancer, or when monitoring a patient already receiving treatment. Here is when it is typically recommended.
Common Symptoms That May Require This Test
The following symptoms may prompt a doctor to order the E2A t Qualitative Test:
- Persistent fatigue and weakness without a clear cause
- Pallor (unusually pale skin)
- Unexplained fever that does not resolve
- Frequent infections
- Easy bruising or unusual bleeding
- Bone or joint pain
- Swollen lymph nodes
Conditions This Test Can Help Detect
This test can help identify the following conditions:
- Precursor B-cell acute lymphoblastic leukaemia (pre-B ALL), where this translocation is found in approximately 25% of affected children
- B-lineage ALL in adults, present in around 4% of newly diagnosed cases
- B-lymphoblastic lymphoma (in rare cases)
- Minimal residual disease (MRD), meaning small numbers of leukaemia cells that remain after treatment
E2A t(1-19)(q23-p13) Qualitative Test for Chronic Disease Monitoring
This test plays an important role in ongoing care for patients with ALL. It helps doctors assess whether treatment has eliminated leukaemia cells or whether residual disease remains. The test may be repeated after induction therapy, consolidation therapy, and periodically during follow-up to monitor for relapse.
How to Prepare and What to Expect
No special preparation is needed before this test. However, there are a few practical steps that will help the process go smoothly.
Do You Need to Fast?
No. Fasting is not required for the E2A t(1-19)(q23-p13) Qualitative Test. You may eat and drink normally before the appointment.
Practical Tips Before Your Test
Keep the following in mind before attending your appointment:
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test
- Inform your doctor about all current medications, especially blood thinners or chemotherapy drugs
- Wear loose, comfortable clothing that allows easy access to the arm for blood collection
- Arrange for someone to accompany you, particularly if a bone marrow sample is being collected
- The bone marrow sample must be processed promptly, so plan to arrive at your scheduled time
Step-by-Step Procedure
This test requires two types of samples: bone marrow aspirate and peripheral blood. Here is what to expect during collection.
Bone Marrow Sample:
- You will be positioned and the skin over the hip bone (or, less commonly, the breastbone) will be cleaned.
- A local anaesthetic is applied to numb the area and minimise discomfort.
- A thin needle is inserted to withdraw a small liquid bone marrow sample (approximately 3 ml).
- The sample is collected into a sodium heparin (green) tube.
Peripheral Blood Sample:
- A small blood sample (approximately 3 ml) is drawn from a vein in your arm using a standard needle.
- This sample is collected into an EDTA (lavender) tube. Both samples are labelled and stored under refrigerated conditions (2 to 8 degrees Celsius) for transport to the laboratory.
Factors That Can Affect Accuracy
The following factors may affect the reliability of your result:
- Poor sample quality or insufficient sample volume
- Delay in processing beyond 24 hours of collection
- Inadequate refrigeration during transport
- Degraded RNA due to improper sample handling
- Incomplete or missing clinical history
- Rare genetic variants at alternative chromosomal breakpoints that standard testing may not detect
Understanding Your E2A t(1-19)(q23-p13) Qualitative Test Results
Results are reported as either "Detected" (positive) or "Not Detected" (negative). A doctor will interpret the result alongside clinical findings, imaging, and other laboratory data.
| Parameter | Expected Result | Unit |
|---|---|---|
| TCF3-PBX1 (E2A-PBX1) fusion gene | Not Detected / Negative | Qualitative |
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
A small number of cases (roughly 5 to 10%) show chromosomal changes that look identical to t(1;19) but do not actually involve the E2A or PBX1 genes. These cases may give atypical results. Additionally, samples with degraded RNA or insufficient quality may produce false-negative results. In such situations, the laboratory may request a repeat sample.
How to Maintain Healthy Levels
While this test does not have a "healthy range" to maintain, the following general steps support wellbeing during evaluation or treatment:
- Follow all prescribed treatment plans and attend scheduled follow-up appointments without gaps
- Support your body with balanced nutrition and adequate rest, particularly during active treatment
- Discuss any new or changing symptoms with your treating haematologist promptly
Lupin Diagnostics E2A t(1-19)(q23-p13) Qualitative Test Price
The E2A t Qualitative Test is priced starting at ₹4,800 at Lupin Diagnostics. Due to the specialised nature of sample collection, particularly bone marrow aspiration which requires clinical supervision, home collection is not available for this test. Patients must visit a Lupin Diagnostics centre.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 4800 |
| CHENNAI | 4800 |
| HYDERABAD | 4800 |
| KOLKATA | 4800 |
| NAVI MUMBAI | 4800 |
| PUNE | 4800 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book your E2A t Qualitative Test Online Booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
This test detects the TCF3-PBX1 fusion gene caused by a translocation between chromosomes 1 and 19. The presence of this fusion gene is a key marker for diagnosing B-cell acute lymphoblastic leukaemia. It also helps doctors guide treatment decisions based on a patient's genetic profile.
This test is recommended for children and adults suspected of or diagnosed with B-lineage ALL, particularly pre-B ALL. It is also used to monitor treatment response and detect signs of disease relapse after therapy.
Bone marrow aspiration is usually performed as an outpatient procedure. Local anaesthesia is used to reduce discomfort. Some patients feel brief pressure or mild pain when the needle is inserted, but the procedure is generally well tolerated.
Results are typically available within 3 days at Lupin Diagnostics. In some cases, depending on sample processing, this may take up to 5 to 7 working days. Your doctor will inform you when to expect the report.
A positive result indicates that the TCF3-PBX1 fusion gene is present in the sample. This finding supports a diagnosis of B-cell ALL and helps doctors select the most appropriate treatment. A positive result should always be discussed with a haematologist-oncologist.
Both bone marrow and peripheral blood are collected for this test. Bone marrow samples generally offer higher sensitivity, especially for detecting minimal residual disease. Peripheral blood provides a supplementary sample for analysis.
No. The E2A t Qualitative Test Home Collection is not available. Because bone marrow aspiration requires clinical supervision and specialised equipment, the test must be performed at a Lupin Diagnostics centre or affiliated facility.
E2A t(1-19)(q23-p13) Qualitative Test: Booking, Price, and Results
